Skip to content
PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Veracyte Announces Key Leadership Promotions to Advance Its Strategic Global Vision
Tina Nova , Ph.D., Appointed President of CLIA U.S. Business Stephane Debono Named General Manager of IVD and EMEA Organizations Giulia C. Kennedy , Ph.D., Named Global Chief Scientific Officer and Chief Medical Officer SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jan. 6, 2022-- Veracyte, Inc .
View HTML
Toggle Summary Veracyte Announces Publication of Data Demonstrating Clinical Utility of Its Envisia Genomic Classifier to Improve IPF Diagnosis
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Dec. 14, 2021-- Veracyte, Inc . (Nasdaq: VCYT) announced today the publication of clinical utility data confirming the ability of the Envisia Genomic Classifier to improve diagnostic and treatment decision-making for patients with idiopathic pulmonary
View HTML
Toggle Summary Veracyte Announces Further European Reimbursement Expansion for Prosigna Breast Cancer Test
Only Test of Its Kind to Be Recommended for Use in All Swedish Healthcare Regions Without Restrictions SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 24, 2021-- Veracyte, Inc. (Nasdaq: VCYT) today announced that the Swedish Medical Technologies Product (MTP) Council has recommended the
View HTML
Toggle Summary Veracyte Announces New Data on Immuno-Oncology Offerings Presented at SITC 2021
Brightplex technology is designed to enable biopharmaceutical researchers to assess the complex tumor micro-environment to aid in development of new therapeutics SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 13, 2021-- Veracyte, Inc. (Nasdaq: VCYT) today announced that new data from three
View HTML
Toggle Summary Veracyte Announces Third Quarter 2021 Financial Results
Total Revenue of $60.4 Million and Volume of 20,972 Tests Company Launches Percepta Nasal Swab and Decipher Bladder Genomic Tests; Completes Acquisition of HalioDx Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 9, 2021-- Veracyte, Inc.
View HTML
Toggle Summary Veracyte Announces Immunoscore Colon Cancer Test Included in ESMO Clinical Practice Guidelines Adapted for Pan-Asia
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 5, 2021-- Veracyte, Inc . (Nasdaq: VCYT) today announced that its Immunoscore Colon Cancer test has been included in the Pan-Asian adapted ESMO 1 Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with localized
View HTML
Toggle Summary New Publication Reinforces Clinical Utility of Afirma Genomic Sequencing Classifier in Thyroid Cancer Diagnosis
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 3, 2021-- Veracyte, Inc. (Nasdaq: VCYT) announced today the publication of new long-term clinical utility data showing that the company’s Afirma Genomic Sequencing Classifier (GSC) helped reduce unnecessary surgeries in patients with indeterminate
View HTML
Toggle Summary Veracyte Announces New Data To Be Presented at SITC 2021 Will Highlight Company’s Immuno-Oncology Capabilities
Brightplex technology, acquired from HalioDx , is designed to help drug developers understand and leverage the tumor micro-environment SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 2, 2021-- Veracyte, Inc. (Nasdaq: VCYT) today announced that three abstracts highlighting the company’s
View HTML
Toggle Summary New Data Demonstrate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier in Tailoring Treatment for Prostate Cancer Patients Experiencing Progression After Surgery
Findings shared today in an oral presentation at ASTRO Annual Meeting 2021 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 26, 2021-- Veracyte, Inc . (Nasdaq: VCYT) announced new data demonstrating the clinical utility of the company’s Decipher Prostate genomic classifier for guiding the timing
View HTML
Toggle Summary Data Presented at ASTRO 2021 Validate Prognostic Value of Decipher Prostate Genomic Test in Newly Diagnosed, Clinically High-Risk Prostate Cancer
- First validation of a gene expression classifier in pre-treatment biopsy samples from prospective randomized trials - SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 25, 2021-- Veracyte, Inc . (Nasdaq: VCYT) announced today that new data being presented at the American Society for Radiation
View HTML